The antimitogenic action of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 149-154

  Patel, Mahendra K ^a   Mulloy, Barbara ^a   Gallagher, Karen L ^a   O'Brien, Leisha ^a   Hughes, Alun D ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

DNA synthesis; ERK1 ERK2 activation; Fucoidan; Heparin; Human vascular smooth muscle

Indexed keywords

DNA; FUCOIDIN; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR BB; POLYSACCHARIDE SULFATE; THROMBOSPONDIN 1;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL SURFACE; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; FETAL CALF SERUM; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0036147718     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612958     Document Type: Article

References (43)

1. Structure and biological activity of heparin
2. Biological activities of polysaccharides from marine algae
3. Structure and anticoagulant activity of sulfated fucans. Comparison between the regular, repetitive, and linear fucans from echinoderms with the more heterogeneous and branched polymers from brown algae
4. A study of fucoidan from the brown seaweed Chorda filum
5. A disaccharide repeat unit is the major structure in fucoidans from two species of brown algae
6. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin
7. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin
8. Binding and internalization of heparin by vascular smooth muscle cells
9. Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization
10. Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect
11. Heparin binding, internalization, and metabolism in vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells
12. Suppression by heparin of smooth muscle cell proliferation in injured arteries
13. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies
14. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans
15. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells
16. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells
17. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells
18. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery
19. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells
20. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle
21. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells
22. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells
23. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells
24. Heparin suppresses sgk, an early response gene in proliferating vascular smooth muscle cells
25. Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells
26. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor
27. Isolation and characterization of a macrophage-derived heparin-binding growth factor
28. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin
29. Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells
30. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex
31. Comparison of effects of platelet-derived growth factor isoforms on signaling and DNA synthesis of human cultured saphenous vein cells
32. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells
33. 3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis
34. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis
35. Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells
36. Cellular biology of human intimal hyperplastic stenosis
37. Effect of angiotensin II on the expression of the early growth response gene c-fos and DNA synthesis in human vascular smooth muscle cells
38. 50) of an enzymatic reaction
39. Different action of heparin and fucoidan on arterial smooth muscle cell proliferation and thrombospondin and fibronectin metabolism
40. Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasia
41. Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity
42. Effect of heparin on vascular smooth muscle cells. I. Cell metabolism
43. Heparin inhibits thrombin-induced mitogen-activated protein kinase signaling in arterial smooth muscle cells